Humacyte, Inc. Regains Nasdaq Minimum Bid Price Compliance

What Happened Humacyte, Inc. (HUMA) announced in an 8-K that Nasdaq has notified the company it has regained compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1). The company previously received a notice on May 4, 2026 that its closing bid had been below $1.00 for the 30 consecutive business days ended May 1, 2026. On June 5, 2026 Nasdaq informed Humacyte the company met the minimum bid-price condition and that the matter is closed.

Key Details

• Nasdaq notice of non-compliance dated May 4, 2026, covering the 30 consecutive business days ended May 1, 2026.
• Cure condition: closing bid of $1.00 or more for at least 10 consecutive business days before the November 2, 2026 deadline.
• Nasdaq notified Humacyte on June 5, 2026 that the company has regained compliance under Nasdaq Listing Rule 5450(a)(1).
• Listing affected: The Nasdaq Global Select Market; Nasdaq considers the matter closed.

Why It Matters Regaining compliance removes the immediate risk of delisting tied to the minimum bid-price rule, preserving the company’s listing status, trading liquidity, and access to public markets. This event does not report financial results or operational changes, but it signals that Humacyte’s share price recovered enough to meet Nasdaq’s listing standard, avoiding further regulatory actions tied to this specific deficiency.